King's College London

Research portal

Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP–PHASE II)

Research output: Contribution to journalArticle

on behalf of the MORE-CRT MPP Investigators, Christophe Leclercq, Haran Burri, Antonio Curnis, Peter Paul Delnoy, Christopher A. Rinaldi, Johannes Sperzel, Kwangdeok Lee, Clay Cohorn, Bernard Thibault

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalAmerican Heart Journal
Volume209
DOIs
Publication statusPublished - 1 Mar 2019

King's Authors

Abstract

Background: Although cardiac resynchronization therapy (CRT) is beneficial in most heart failure patients, up to 40% do not respond to CRT. Data from the MultiPoint Pacing (MPP) IDE trial and MORE-CRT MPP–PHASE I study suggest improved response in subjects in the MPP arm—programmed with wide left ventricular (LV) electrode anatomical separation (≥30 mm) and shortest timing delays of 5 milliseconds (MPP-AS)—compared with quadripolar biventricular (BiV) pacing. Study design: The MORE-CRT MPP–PHASE II trial is a prospective, randomized, multicenter study to assess the 6-month impact of MPP programmed to mandated MPP-AS settings in subjects who do not respond to 6 months of BiV pacing (MPP OFF). Approximately 5,000 subjects with a standard CRT indication will be enrolled and implanted with a quadripolar CRT system (Abbott) capable of delivering MPP. Only BiV pacing is activated at implant. At 6 months, subjects classified as CRT nonresponders (<15% reduction in LV end-systolic volume) are randomized (1:1) to MPP or continued BiV pacing. The mandated MPP parameters (eg, MPP-AS) are programmed to subjects randomized to the MPP arm. At 12 months, the 2 groups will be compared to determine if there is a difference in CRT response rate. Conclusions: This trial will evaluate whether MPP programmed to mandated MPP-AS settings improves LV reverse remodeling and clinical response to CRT in patients who fail to respond to 6 months of BiV pacing (www.clinicaltrials.gov identifier NCT02006069).

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454